ZA200201374B - Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction. - Google Patents
Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction. Download PDFInfo
- Publication number
- ZA200201374B ZA200201374B ZA200201374A ZA200201374A ZA200201374B ZA 200201374 B ZA200201374 B ZA 200201374B ZA 200201374 A ZA200201374 A ZA 200201374A ZA 200201374 A ZA200201374 A ZA 200201374A ZA 200201374 B ZA200201374 B ZA 200201374B
- Authority
- ZA
- South Africa
- Prior art keywords
- antagonist
- lhrh antagonist
- short
- induction treatment
- administration
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 31
- 206010065789 Fallopian tube obstruction Diseases 0.000 title claims description 23
- 208000030843 hydrosalpinx Diseases 0.000 title claims description 23
- 230000002357 endometrial effect Effects 0.000 title claims description 21
- 230000035755 proliferation Effects 0.000 title claims description 18
- 208000000450 Pelvic Pain Diseases 0.000 title claims description 14
- 230000001684 chronic effect Effects 0.000 title claims description 14
- 230000001225 therapeutic effect Effects 0.000 title claims description 13
- 239000002474 gonadorelin antagonist Substances 0.000 claims description 187
- 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 claims description 130
- 238000011419 induction treatment Methods 0.000 claims description 85
- 238000011282 treatment Methods 0.000 claims description 44
- 239000013543 active substance Substances 0.000 claims description 38
- 239000003433 contraceptive agent Substances 0.000 claims description 34
- 230000002254 contraceptive effect Effects 0.000 claims description 33
- 229940127234 oral contraceptive Drugs 0.000 claims description 31
- 239000003539 oral contraceptive agent Substances 0.000 claims description 31
- 230000003637 steroidlike Effects 0.000 claims description 31
- 239000003435 antirheumatic agent Substances 0.000 claims description 30
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testosterone Natural products O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 29
- 230000000202 analgesic effect Effects 0.000 claims description 29
- 239000003098 androgen Substances 0.000 claims description 29
- 239000008194 pharmaceutical composition Substances 0.000 claims description 29
- 229960003604 testosterone Drugs 0.000 claims description 28
- 150000003515 testosterones Chemical class 0.000 claims description 28
- 210000002966 serum Anatomy 0.000 claims description 17
- 230000003442 weekly effect Effects 0.000 claims description 16
- 239000000262 estrogen Substances 0.000 claims description 14
- 229940011871 estrogen Drugs 0.000 claims description 14
- 108700008462 cetrorelix Proteins 0.000 claims description 13
- 230000011599 ovarian follicle development Effects 0.000 claims description 12
- 229960003230 cetrorelix Drugs 0.000 claims description 11
- NOENHWMKHNSHGX-IZOOSHNJSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-(ca Chemical compound C([C@H](C(=O)N[C@H](CCCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 NOENHWMKHNSHGX-IZOOSHNJSA-N 0.000 claims description 9
- 108010023617 abarelix Proteins 0.000 claims description 9
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 claims description 9
- 229960002184 abarelix Drugs 0.000 claims description 9
- 108010070670 antarelix Proteins 0.000 claims description 9
- 108700032141 ganirelix Proteins 0.000 claims description 9
- GJNXBNATEDXMAK-PFLSVRRQSA-N ganirelix Chemical compound C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 GJNXBNATEDXMAK-PFLSVRRQSA-N 0.000 claims description 9
- 229960003794 ganirelix Drugs 0.000 claims description 9
- 108010083551 iturelix Proteins 0.000 claims description 9
- QRYFGTULTGLGHU-NBERXCRTSA-N iturelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCCNC(=O)C=1C=NC=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)CCCNC(=O)C1=CC=CN=C1 QRYFGTULTGLGHU-NBERXCRTSA-N 0.000 claims description 9
- 229950011372 teverelix Drugs 0.000 claims description 9
- KATZUZNTRINHDT-HALMFYTRSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]-methylamino]-3-(4-hydroxyphenyl)propanoyl]amino Chemical compound C([C@@H](C(=O)N[C@H](CCCCNC(N)=O)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 KATZUZNTRINHDT-HALMFYTRSA-N 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 claims 4
- 201000009273 Endometriosis Diseases 0.000 description 23
- 210000001519 tissue Anatomy 0.000 description 17
- 238000002560 therapeutic procedure Methods 0.000 description 15
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 14
- 229930182833 estradiol Natural products 0.000 description 14
- 229960005309 estradiol Drugs 0.000 description 14
- KFEFLCOCAHJBEA-ANRVCLKPSA-N cetrorelix acetate Chemical compound CC(O)=O.C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 KFEFLCOCAHJBEA-ANRVCLKPSA-N 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000001629 suppression Effects 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 7
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 6
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 6
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
- 235000012208 gluconic acid Nutrition 0.000 description 6
- 239000000174 gluconic acid Substances 0.000 description 6
- 230000003054 hormonal effect Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 230000002175 menstrual effect Effects 0.000 description 5
- 208000025661 ovarian cyst Diseases 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 4
- 230000037416 cystogenesis Effects 0.000 description 4
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 4
- 229960000766 danazol Drugs 0.000 description 4
- 210000004696 endometrium Anatomy 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- DPZHKLJPVMYFCU-UHFFFAOYSA-N 2-(5-bromopyridin-2-yl)acetonitrile Chemical compound BrC1=CC=C(CC#N)N=C1 DPZHKLJPVMYFCU-UHFFFAOYSA-N 0.000 description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 description 3
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 3
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 3
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 238000005115 demineralization Methods 0.000 description 3
- 230000002328 demineralizing effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 3
- 229940121381 gonadotrophin releasing hormone (gnrh) antagonists Drugs 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000186 progesterone Substances 0.000 description 3
- 229960003387 progesterone Drugs 0.000 description 3
- 239000000583 progesterone congener Substances 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- DPYIXBFZUMCMJM-BTJKTKAUSA-N (z)-but-2-enedioic acid;ethyl n-[2-amino-6-[(4-fluorophenyl)methylamino]pyridin-3-yl]carbamate Chemical compound OC(=O)\C=C/C(O)=O.N1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 DPYIXBFZUMCMJM-BTJKTKAUSA-N 0.000 description 2
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 2
- 208000005641 Adenomyosis Diseases 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 2
- 206010060800 Hot flush Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 206010046798 Uterine leiomyoma Diseases 0.000 description 2
- 159000000021 acetate salts Chemical class 0.000 description 2
- 230000001548 androgenic effect Effects 0.000 description 2
- 230000003356 anti-rheumatic effect Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 229940124301 concurrent medication Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 201000009274 endometriosis of uterus Diseases 0.000 description 2
- 229960002568 ethinylestradiol Drugs 0.000 description 2
- 230000003152 gestagenic effect Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 238000002357 laparoscopic surgery Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000013160 medical therapy Methods 0.000 description 2
- 230000008058 pain sensation Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- RPGGYYVWJTWVMS-ZPSVQYCPSA-N (8r,9s,10r,13s,14s,17r)-17-ethynyl-10,13-dimethyl-1,2,3,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C1CC[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPGGYYVWJTWVMS-ZPSVQYCPSA-N 0.000 description 1
- -1 ) Yermonil® Chemical compound 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000766026 Coregonus nasus Species 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 description 1
- 208000004483 Dyspareunia Diseases 0.000 description 1
- 208000009849 Female Genital Neoplasms Diseases 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- YNVGQYHLRCDXFQ-XGXHKTLJSA-N Lynestrenol Chemical compound C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 YNVGQYHLRCDXFQ-XGXHKTLJSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 229960001865 cetrorelix acetate Drugs 0.000 description 1
- 229940112106 cetrotide Drugs 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000010102 embolization Effects 0.000 description 1
- 210000005168 endometrial cell Anatomy 0.000 description 1
- 201000002585 endosalpingiosis Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 229960001751 fluoxymesterone Drugs 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- 229960003667 flupirtine Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 229940094892 gonadotropins Drugs 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 229960001910 lynestrenol Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012961 medicinal therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000001792 virilizing effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
Description
‘a
Method for the therapeutic management of extrauterine proliferation of N endometrial tissue, chronic pelvic pain and fallopian tube obstruction ' 5 .
Endometriosis is one of the most frequently encountered pathologies diagnosed amongst gynecological patients. For example, between 10% and 25% of women presenting with gynecological symptoms in UK and in the USA are affected. Clinical diagnosis is made usually by laparoscopic observation of hemorrhagic or fibrotic foci on the pelvic organs. The ectopic endometrial tissue responds to ovarian hormones undergoing cyclic changes. The cyclical bleeding from the endometric deposit contributes to a local inflammatory reaction. Endometriosis commonly affects women during their childbearing years with an incidence of at least 1% (see Shaw, RW. (1993), An Atlas of Endometriosis. The Parthenon Publishing Group).
Endometriosis is usually classified into endometriosis (genitalis) interna (adenomyosis), endometriosis genitalis externa and endometriosis extragenitalis.
Chronic pelvic pain may occur either in relation to endometriosis or as an independent disease.
Fallopian tube obstruction (FTO) is a relatively common disease and may account to for up to 20 % of cases of tubal infertility (see Winfield, A.C. et al., Apparent cornual occlusion in hysterosalpingography: Reversal by glucagon. AJR Am J Roentgenol 1982; 139: 525 — 527). :
Background information and Prior Art
Sampson suggested that menstrual regurgitation and subsequent implantation of endometrial tissue on the peritoneal face results in endometriosis [Sampson, J.A.
CONFIRMATION COPY
'. wo o121194 , PCT/EP00/09212
LS (1927), Peritoneal endometriosis due to menstrual dissemination of the endometrial tissue into the peritoneal cavitiy. Am. J. Obstet. Gynecol., 14, 422.]
Several aetiologic factors may be involved in the pathogenesis of endometriosis :
Dmowski et. al. suggested that genetic and immunological factors lead to endometriosis [Dmowski, W.P., Steele, RW. and Baker, G.F. (1981). Deficient cellular immunity in endometriosis. Am. J. Obstet. Gynecol., 141, 377]
Vascular and lymphatic embolization to distant sites has been demonstrated and explains the (rare) finding of endometriosis outside the peritoneal cavity, e.g. skin, lung, kidney.
Cells lining the Mallerian duct arise from primitive cells which differentiate into peritoneal cells and the cells on the surface of the ovaries. It is proposed that these aduit cells undergo de-differentiation back to their primitive origin and then transform into endometrial cells [ Levander, G. (1941), Bone formation by induction. An experimental study. Arch. Klin. Chir., 202, 497] . Dysmenorrhea, acute or chronic pelvic pain, dyspareunia, and infertility perform the most frequent clinical symptoms reported.
FTO represents a heterogenous group of underlying pathology, preliminary intrinsic occlusion or extrinsic compression from estrogen-sensitive disorders, such as endometriosis, adenomyosis, endosalpingiosis, and myomata. FTO is frequently diagnosed by hysterosalpingography, besides laparascopy.
First choice of treatment comprises laparoscopic removal of endometric lesions.
This procedure may be followed by the treatment with Danazol or LHRH agonist (for a period of six months). Women being treated with Danazol might experience gastrointestinal and hepatic disorders as well as severe androgenic side effects.
It was also proposed from a theoretical viewpoint for treatment of endometriosis and uterine myoma to use the immediate suppression by administration of a LHRH antagonist to reducing the duration of treatment and faster improvement of subjective symtoms [Th. Reissmann et al. Human Reproduction vol. 10 No. 8 pp.1974-1981,(1995)]
Further Hodgen teaches in the US Patent 5,658,884 a regime for therapeutic . management of a gonadal dependent condition by reducing the estrogen supply by To means of long-term administration of an GnRH antagonist for 6 months or longer in an amount effective to inhibit proliferation of endometrial tissue without substantially - stopping the production of endogenous estrogen. For this purpose, Hodgen teaches : such a regimen or dose of GnRH antagonist to achieve a 24 hour serum estradiol level in the range of about 25 to 50 and preferably about 35 to 45 pg/ml. However,
Hodgen does not describe estradiol serum levels oscillating between 50 pg/ml and 75 pg/ml. Moreover, Hodgen only teaches in the US Patent 5,668,884 a continuous long-term treatment (on a daily or periodic basis, the latter meaning a weekly or monthly administration) but not a short-term induction treatment for only 4 to 12 weeks. Hodgen also does not describe any combination therapy comprising the
GnRH antagonist in the treatment of endometrosis. The treatment is only described on monkeys and also includes the performance of a costly and repeated progesterone challenge test to provide an 24 hour average serum estradiol level of
Lo '30to 50 pg/ml. TT TT - :
As a consequence of the flare-up effect of LHRH-agonistic therapy an exacerbation of symptoms might occur during some days. Following prolonged treatment which is required to avoid the re-proliferation of endometric tissue hormonal withdrawal symptoms as well as demineralization of bones occur.
Therefore, effective drug therapy should immediately reduce the residual extrauterine endometrial tissue present after laparoscopic surgery. Duration of therapy should be only 4 to 12 weeks without the occurrence of any major hormonal withdrawal symptoms or ovarian cyst formation.
LHRH antagonists exert an immediate onset of hormonal suppression, and therefore benign gynecological tumors, such as uterine fibroids decrease within short time [Human Reproduction 1998, 13]
Object of the Invention
‘oo Woo 4 PCT/EP00/09212 ¢ The present invention relates to the improvement of the medical treatment of ’ extrauterine proliferation of endometrial tissue, i. e. the administration of LHRH antagonists in patients with clinical symptoms of endometriosis, the improvement ) consisting of : immediate reduction of ectopic endometrial tissue immediate cessation of symptoms, e.g. severe pain, chronic pelvic pain and dysmenorrhea prevention of any progress of the disease avoidance of hormonal withdrawal symptoms prevention of ovarian cyst formation, demineralization of bones as well as of gastrointestinal or hepatic disorders.
The inventive medical therapy can start in the early to mid follicular phase, preferably on cycle day one to three. During the treatment the estradiol serum concentration levels are kept between 35 pg/ml and 80 pg/ml, preferably between about 45-75 pg/ml, more preferably between about 50-75 pg/ml. The LHRH antagonist is administered only for 4 to 12 weeks (short-term induction treatment), either by daily, weekly or monthly administration. Following the short-term induction treatment, the administration of a contraceptive, a non-steroidal anti-rheumatic, an analgetic, an androgen other than 17-alpha-alkyl substituted testosterone or any combinations thereof is provided according to the present invention.
Summary of the Invention in the treatment of extrauterine endometrial tissue with an LHRH antagonist, therapy is started on menstrual cycle day one to three. Before starting LHRH- antagonist therapy the diagnosis is performed by laparoscopy.
In cases of severe pain, LHRH antagonist therapy might be initiated without prior laparascopy.
Therapy will continue until clinical symptomatology has resolved and no proliferation of the endometrium is seen. Due to the immediate onset of suppression of the gonadotropins LH and FSH as well of sex steroids estradiol and progesterone no
-5- " y further proliferation of the endometrium occurs. Benign tumors or other sex steroid . dependent lesions, like endometriosis decrease within four to twelve weeks of : therapy. Due to the lack of flare-up no ovarian cysts develop.
Furthermore, no hormonal withdrawal symptoms are seen as the estradiol values are kept in the range of the early follicular phase of 35 to 80 pg/ml, preferably between about 45-75 pg/ml, more preferably between about 50-75 pg/ml without further increase or decrease. No titering of the dosage of the LHRH antagonist , e.g. by conducting a costly progesterone challenge test, is necessary.
The method of therapeutic management of extrauterine proliferation of endometrial tissue the improvement according to the invention therefore embraces: immediate reduction of ectopic endometrial tissue prevention of any progress of the disease 15s avoidance of hormonal withdrawal symptoms - "prevention of ovarian cyst formation, demineralization of bones as well as of } gastrointestinal or hepatic disorders start of medical therapy on cycle day one to three and maintenance of estradiol levels at values of the early follicular phase throughout the entire duration of treatment by means of administration of a LHRH antagonist wherein the antagonist is preferabely cetrorelix, teverelix, ganirelix, antide or abarelix. The antagonist can also be the LHRH antagonist D-63153 (Ac-D-Nal-D-pCl-Phe-D-Pal-Ser-N-Me-Tyr-D-
Hci-Nie-Arg-Pro-D-Ala-NH2) as described in the German Patent Application No. 199 11 771.3 filed on March 11, 1999.
The LHRH antagonist may be given for 4 to 12 weeks in a weekly dose of 3 to 10 mg per week or for 4 to 12 weeks in a daily dose of 0.25 mg to 0.5 mg/day.
It is also possible to give the LHRH antagonist 4 to 12 weeks in a monthly dose of 12 to 40 mg per month.
In a repeat therapeutic treatment the LHRH antagonist is given for 4 to 12 weeks and the treatment is repeated two or three times a year, whereby a repeated
'. WO0121194 5 PCT/EP00/09212 ¢ treatment does not following directly after a short-term induction treatment. Usually a ) period of time of weeks or months, where no LHRH antagonist is administered, is between the end of the short-term induction treatment and the start of the repeat ) treatment.
To demonstrate the feasibility to maintain a low estradiol secretion under adjusted
LHRH- antagonist treatment so that a therapeutic suppression occurs without withdrawal symtoms nine patients with confirmed endometriosis were treated with 3 mg of Cetrorelix acetate s.c. by weekly administration for 8 weeks. While patients compliance was excellent avoiding any hot flushes or other withdrawal symptoms and without any progress of the disease confimed by 2 ™ look laparascopy the mean estradiol serum concentrations oscillated between 37 pg/ml and 64 pg/ml, preferably between 45-75 pg/ml, more preferably between about 50-75 pg/ml. Histological biopsies showed no proliferation of the endometrium at the end of treatment. No ovarian cyst formation occurred.
The figure 1 shows the continuous estradiol suppression to values of the early follicular phase (range of 35 pg/ml to 80 pg/ml, preferably between 45-75 pg/ml, more preferably between about 50-75 pg/ml) obtained in patients with endometriosis by a weekly dose of 3 mg of Cetrorelix (LHRH antagonist) for 8 weeks. Immediate : and continuous suppression of estradiol levels is obtained without any signs of estradiol withdrawal symptoms and without proliferation of the endometrium at the end of treatment.
Fig. 2 shows estradiol serum levels after administration of cetrorelix at a weekly dose of 1 mg resp. 3 mg once per week. The estradiol serum levels are between about 35- 80 pg/ml, preferably between about 45-75 pg/ml, more preferably between about 50- 75 pg/ml.
The endometriosis patient with distinctive symptomatic pain is suffering from a chronic disease. Surgical methods in sense of curative therapy as well as medicinal treatment to suppress the sexual steroid secretion of the patient often result only in a temporary improvement. The relapse rate of the discomforts is very high and about 70% within 5 years after finishing therapy (Schweppe, 1999). :
At the same time the radical surgical therapy and the suppression of the estrogen : s secretion leads to considerable side effects. The radical surgical therapy in sense of hysterectomy with bilateral adnexectomy is no adequate therapy for the younger, premenopausal woman. The chronical lack of estrogen leads to the following vegetative symptoms: hot flashes, sweating, dryness of the vagina, depressive feelings and also holds the risk of osteoporosis. The alternative therapy with the synthetic steroidal compound Danazol may cause virilizing symptoms because of the androgenic effect.
Aim of the medicinal therapy of patients with endometriosis with symptomatic pain is to obtain a treatment without side effects, especially avoiding the negative effects of : 15 estrogen suppression and which is long-lasting after finishing therapy. The specific 2 "pharmacological mode of action of LHRH antagonists allows new possibilities for ] treatment of endometriosis.
The weekly administration of an adequate dose of an LHRH antagonist, e.g. 3mg
Cetrotide® s.c./ per week over a period of eight weeks leads to a controlled suppression of estrogen secretion so that serum concentrations between about 35 pg/ml and about 80 pg/ml, preferably between about 45-75 pg/ml, more preferably between about 50-75 pg/ml are obtained. In this serum concentration range no vegetative symptoms arise. Also the development of osteoporosis can be avoided.
The symptomatic pain will be effectively suppressed in all stages of the disease (rAFS | — IV). In the stages rAFS | — Il a clinical regression of the disease in sense of decrease of the implantation area is noticed (Felberbaum et. al., 2000).
In a preferred embodiment of this invention, after this treatment period of eight to twelve weeks the patient could take a contraceptive, preferably an oral contraceptive, preferably with gestagen components, unless there is a wish for pregnancy. in this connection combinations with Lynestronol 2 mg with 0,04 mg
‘won 8. PCT/EP00/09212 " Ethinylestradiol or 2,5mg Lynestrenol with 0,05 mg of Ethinylestradiol (e.g. ) Yermonil®, Lyn-ratiopharm-Sequenz®) have to be mentioned. ) A combination therapy with androgens other than 17-alpha-alkyl substituted testosterones such as danazol may also be applied subsequently to the short-term induction regimen with the LHRH antagonist either alone or in combination with non- steroidal anti-rheumatics and/or anaigetics. An example for a suitable androgene is halotestin™ (fluoximesterone).
The treatment with a contraceptive, preferably an oral contraceptive, preferably containing gestagens, should be individually continued until typical pain sensation occurs. In this stage the patient will have relatively small menstrual bleeding as an effect of the gestagen component of this contraceptive, preferably oral contraceptive.
For covering also the especially critical pre-menstrual and menstrual days with regard to pain sensation in this phase a concomitant medication with appropriate } non-steroidal anti-rheumatic drugs, e.g. diclophenac, ibuprofen, indometeacin, oxicam derivates or acetylsalicylic acid may be given. Also an analgetic such as flupirtinmaleat (Katadolon®) can be administered.
If further pain symptoms occur during this combination therapy with gestagenic contraceptives, preferably oral contraceptives, a daily, weekly or monthly therapy with the adequate dose of an LHRH antagonist as described above may be repeated. Detailed information on the respective treatment options are given below.
If the patient is absolutely free of pain treatment can be changed to gestagenic contraceptive, preferably oral contraceptive,s in combination with concomitant medication of appropriate non-steroid anti-rheumatic drugs or analgetics.
This therapy using the intermittent administration of an LHRH antagonist leads to a new and innovative unlimited treatment without side effects and lowers treatment burden for the patient significantly.
Pharmaceutical Formulations Suitable for Treatment :
Pharmaceutical formulations of the LHRH antagonist suitable for the therapeutic : s management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction may be for example a) acetate salt formulations in the concentration of 1 mg/1 ml or lower where the powder may be dissolved in Water for Injection (Wfl) or in Gluconic Acid (GA); b) acetate salt formulations in the concentration of 1.5 mg/1 ml to 5.0 mg /1 ml, preferably 2.5 mg/1 ml where the powder may be dissolved in Water for Injection (WH) or in Gluconic Acid (GA), - 15 c) pamoate salt formulations in the concentration of 10 mg/1 ml to 30 mg/1 mi, preferably 15 mg/1 ml where the lyophylisate powder may be dissolved in
Gluconic Acid (GA) or in Water for Injection (Wl.
According to one aspect of the present invention in the method of therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and/or fallopian tube obstruction (FTO), the improvement consisting of administration of an LHRH antagonist in the form of a short-term induction treatment for a period of about 4 to 12 weeks to a patient in need of such treatment, whereby subsequently the administration of the LHRH antagonist is ceased, is provided. . 25
The duration of the short term induction treatment is about 4 to about 12 weeks, that means that the treatment can be between about 28 to about 84 days or from about one to about three months.
According to another aspect of the present invention in a method as mentioned above the improvement is provided, wherein the LHRH antagonist is administered such that the estrogen serum concentration level is between about 35 pg/ml and
'C woouz1194 10. : PCT/EP00/09212 a about 80 pg/ml, preferably between about 45-75 pg/ml, more preferably about 50-75 pg/ml.
According to another aspect of the present invention in a method as mentioned above the improvement is provided, characterized in that the short-term induction treatment with the LHRH antagonist is followed by administration of a contraceptive, preferably an oral contraceptive.
According to another aspect of the present invention in a method as mentioned above the improvement is provided, characterized in that the short-term induction treatment with the LHRH antagonist is followed by administration of a non-steroidal anti-rheumatic agent.
According to another aspect of the present invention in a method as mentioned above the improvement is provided, characterized in that the short-term induction treatment with the LHRH antagonist is followed by administration of an analgetic.
According to another aspect of the present invention in a method as mentioned : above the improvement is provided, characterized in that the short-term induction : 20 treatment with the LHRH antagonist is followed by administration of an androgen other than a 17-alpha-alky! substituted testosterone.
According to another aspect of the present invention in a method as mentioned above the improvement is provided, characterized in that the short-term induction treatment with the LHRH antagonist is followed by the combined or separate administration of one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof.
According to another aspect of the present invention in a method as mentioned above the improvement is provided, characterized in that the LHRH antagonist is administered starting in the early to mid follicular phase, preferably on cycle day one to three.
According to another aspect of the present invention in a method as mentioned s above the improvement is provided, characterized in that the LHRH antagonist is selected from the group consisting of cetrorelix, teverelix, ganirelix, antide, abarelix and D-63153.
According to another aspect of the present invention in a method as mentioned above the improvement is provided, characterized in that the LHRH antagonist is administered during the short-term induction treatment for 4 to 12 weeks at a weekly dose of 3 to 10 mg per week.
According to another aspect of the present invention in a method as mentioned above the improvement is provided, characterized in that the LHRH antagonist is oo "administered during the short-term induction treatment for 4 to 12 weeks at a daly ~~
G dose of 0.25 mg to 0.5 mg/day.
According to another aspect of the present invention in a method as mentioned above the improvement is provided, characterized in that the LHRH antagonist is administered during the short-term induction treatment for 4 to 12 weeks at a monthly dose of 12 to 40 mg per month.
According to another aspect of the present invention in a method as mentioned above the improvement is provided, characterized in that the LHRH antagonist is given for the induction treatment during 4 to 12 weeks and the treatment is repeated two or three times a year.
According to a further aspect of the present invention a pharmaceutical composition for treating extrauterine proliferation of endometrial tissue, chronic pelvic pain and/or fallopian tube obstruction (FTO) comprising an LHRH antagonist and optionally one or more agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic agent, an
‘. WO0o0121194 12. PCT/EP00/09212 ¢ androgen agent other than a 17-alpha-alkyl substituted testosterone or any combinations thereof, optionally together with pharmaceutically acceptable excipients, whereby the LH-RH antagonist is administered to a patient in need thereof in a short term induction treatment for a period of about 4 to 12 weeks, then the administration of the LH-RH antagonist is ceased and optionally the one or more agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof, are administered together or separately to the patient is provided.
Suitable excipients and dosage forms are for example described by K.H. Bauer, K -
H. Fréomming and C. FGhrer, Lehrbuch der Pharmazeutischen Technologie, 6" edition, Stuttgart 1999, pages 163-186 (excipients) and pages 227-386 (dosage forms), including the references as cited therein. g The LH-RH antagonist can be administered for example sucutaneous (s.c.), intramuscular (i.m.) or inhalative. The agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alky! substituted testosterone or any combinations thereof can be administered as known in the art (see for example the German, European or U.S. pharmacopoeia), preferably oral or inhalative.
According to another aspect of the present invention, a pharmaceutical composition as mentioned above is provided wherein the LHRH antagonist is administered such that the estrogen serum concentration level is between about 35 pg/ml and about 80 pg/ml, preferably between about 45-75 pg/ml, more preferably about 50-75 pg/ml.
According to another aspect of the present invention, a pharmaceutical composition as mentioned above is provided wherein the short-term induction treatment with the
LHRH antagonist is followed by administration of a contraceptive, preferably an oral contraceptive.
According to another aspect of the present invention, a pharmaceutical composition as mentioned above is provided wherein the short-term induction treatment with the
LHRH antagonist is followed by administration of a non-steroidal anti-rheumatic agent. )
According to another aspect of the present invention, a pharmaceutical composition as mentioned above is provided wherein the short-term induction treatment with the
LHRH antagonist is followed by administration of an analgetic.
According to another aspect of the present invention, a pharmaceutical composition as mentioned above is provided wherein the short-term induction treatment with the
LHRH antagonist is followed by administration of an androgen other than a 17- alpha-alkyi substituted testosterone. : 15 According to another aspect of the present invention, a pharmaceutical composition - as mentioned above is provided wherein the short-term induction treatment with the ~~
LHRH antagonist is followed by the combined or separate administration of one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alky! substituted testosterone or any combinations thereof.
According to another aspect of the present invention, a pharmaceutical composition as mentioned above is provided wherein the LHRH antagonist is administered starting in the early to mid follicular phase, preferably on cycle day one to three.
According to another aspect of the present invention, a pharmaceutical composition as mentioned above is provided wherein the LHRH antagonist is selected from the group consisting of cetrorelix, teverelix, ganirelix, antide, abarelix and D-631563.
According to another aspect of the present invention, a pharmaceutical compasition as mentioned above is provided wherein the LHRH antagonist is administered during fo WO 0121194 "ve PCT/EP00/09212 « the short-term induction treatment for 4 to 12 weeks at a weekly dose of 3 to 10 mg per week.
According to another aspect of the present invention, a pharmaceutical composition as mentioned above is provided wherein the LHRH antagonist is administered during the short-term induction treatment for 4 to 12 weeks at a daily dose of 0.25 mg to 0.5 mg/day.
According to another aspect of the present invention, a pharmaceutical composition as mentioned above is provided wherein the LHRH antagonist is administered during the short-term induction treatment for 4 to 12 weeks at a monthly dose of 12 to 40 mg per month.
According to another aspect of the present invention, a pharmaceutical composition as mentioned above is provided wherein the LHRH antagonist is given for the induction treatment during 4 to 12 weeks and the treatment is repeated two or three times a year.
According to another aspect of the present invention, a pharmaceutical composition as mentioned above is provided, wherein the the one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non- steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof, are in the same or separate dosage forms.
According to another aspect of the present invention, a use of an LH-RH antagonist for the preparation of a medicament for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and/or fallopian tube obstruction (FTO), whereby the LHRH antagonist is administered in the form of a short-term induction treatment for a period of about 4 to 12 weeks to a patient in need of such treatment and then the administration of the LHRH antagonist is ceased, is provided.
According to another aspect of the present invention, a use of an LH-RH antagonist as mentioned above is provided wherein the LHRH antagonist is administered such : that the estrogen serum concentration level is between about 35 pg/ml and about 80 pg/ml, preferably between about 45-75 pg/mi, more preferably about 50-75 pg/ml.
According to another aspect of the present invention, a use of an LH-RH antagonist as mentioned above is provided, wherein the short-term induction treatment with the
LHRH antagonist is followed by administration of a contraceptive, preferably an oral : contraceptive.
According to another aspect of the present invention, a use of an LH-RH antagonist as mentioned above is provided, wherein the short-term induction treatment with the
LHRH antagonist is followed by administration of a non-steroidal anti-rheumatic agent. -
Co According to another aspect of the present invention, a use of an LH-RH antagonist ~~ as mentioned above is provided, wherein the short-term induction treatment with the
LHRH antagonist is followed by administration of an analgetic.
According to another aspect of the present invention, a use of an LH-RH antagonist as mentioned above is provided, wherein the short-term induction treatment with the
LHRH antagonist is followed by administration of an androgen other than a 17- alpha-alkyl substituted testosterone.
According to another aspect of the present invention, a use of an LH-RH antagonist as mentioned above is provided, wherein the short-term induction treatment with the
LHRH antagonist is followed by the combined or separate administration of one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive,, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof.
‘ Wwoo12119 16 PCT/EP00/09212 . According to another aspect of the present invention, a use of an LH-RH antagonist as mentioned above is provided, wherein the LHRH antagonist is administered starting in the early to mid follicular phase, preferably on cycle day one to three.
According to another aspect of the present invention, a use of an LH-RH antagonist as mentioned above is provided, wherein the LHRH antagonist is selected from the group consisting of cetrorelix, teverelix, ganirelix, antide, abarelix and D-63153.
According to another aspect of the present invention, a use of an LH-RH antagonist as mentioned above is provided, wherein the LHRH antagonist is administered during the short-term induction treatment for 4 to 12 weeks at a weekly dose of 3 to 10 mg per week.
According to another aspect of the present invention, a use of an LH-RH antagonist as mentioned above is provided, wherein the LHRH antagonist is administered during the short-term induction treatment for 4 to 12 weeks at a daily dose of 0.25 mg to 0.5 mg/day.
According to another aspect of the present invention, a use of an LH-RH antagonist as mentioned above is provided, wherein the LHRH antagonist is administered during the short-term induction treatment for 4 to 12 weeks at a monthly dose of 12 to 40 mg per month.
According to another aspect of the present invention, a use of an LH-RH antagonist as mentioned above is provided, wherein the LHRH antagonist is given for the induction treatment during 4 to 12 weeks and the treatment is repeated two or three times a year.
According to another aspect of the present invention, a use of an LH-RH antagonist and one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone, or any combinations thereof, for the preparation of a medicament for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain - and/or fallopian tube obstruction (FTO), whereby the LHRH antagonist is administered in the form of a short-term induction treatment for a period of about 4 to 12 weeks to a patient in need of such treatment, then the administration of the LHRH ) antagonist is ceased and the one or more active agent selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti- rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted : testosterone, or any combinations thereof, are administered together or separately to ) the patient, is provided.
According to another aspect of the present invention the use of an LH-RH antagonist and one or more active agents as mentioned above is provided, wherein the LHRH antagonist is administered such that the estrogen serum concentration level is : between about 35 pg/ml and about 80 pg/ml, preferably between about 45-75 pg/ml, more preferably about 50-75 pg/ml. x According to another aspect of the present invention the use of an LH-RH antagonist ¥ and one or more active agents as mentioned above is provided, wherein the short- term induction treatment with the LHRH antagonist is followed by administration of a contraceptive, preferably an oral contraceptive.
According to another aspect of the present invention the use of an LH-RH antagonist and one or more active agents as mentioned above is provided, wherein the short- term induction treatment with the LHRH antagonist is followed by administration of a non-steroidal anti-rheumatic agent.
According to another aspect of the present invention the use of an LH-RH antagonist and one or more active agents as mentioned above is provided, wherein the short- term induction treatment with the LHRH antagonist is followed by administration of an analgetic.
According to another aspect of the present invention the use of an LH-RH antagonist and one or more active agents as mentioned above is provided, wherein the short-
‘ WOo01/21194 18 PCT/EP00/09212 a term induction treatment with the LHRH antagonist is followed by administration of an androgen other than a 17-alpha-alky! substituted testosterone. ) According to another aspect of the present invention the use of an LH-RH antagonist and one or more active agents as mentioned above is provided, wherein the short- term induction treatment with the LHRH antagonist is followed by the combined or separate administration of one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti- rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof.
According to another aspect of the present invention the use of an LH-RH antagonist and one or more active agents as mentioned above is provided, wherein the LHRH antagonist is administered starting in the early to mid follicular phase, preferably on cycle day one to three. . According to another aspect of the present invention the use of an LH-RH antagonist and one or more active agents as mentioned-above is provided, wherein the LHRH - . antagonist is selected from the group consisting of cetrorelix, teverelix, ganirelix, antide, abarelix and D-63153.
According to another aspect of the present invention the use of an LH-RH antagonist and one or more active agents as mentioned above is provided, wherein the LHRH antagonist is administered during the short-term induction treatment for 4 to 12 weeks at a weekly dose of 3 to 10 mg per week.
According to another aspect of the present invention the use of an LH-RH antagonist and one or more active agents as mentioned above is provided, wherein the LHRH antagonist is administered during the short-term induction treatment for 4 to 12 weeks at a daily dose of 0.25 mg to 0.5 mg/day.
According to another aspect of the present invention the use of an LH-RH antagonist and one or more active agents as mentioned above is provided, wherein the LHRH antagonist is administered during the short-term induction treatment for 4 to 12 weeks at a monthly dose of 12 to 40 mg per month.
According to another aspect of the present invention the use of an LH-RH antagonist . s and one or more active agents as mentioned above is provided, wherein the LHRH antagonist is given for the induction treatment during 4 to 12 weeks and the treatment is repeated two or three times a year.
Claims (53)
1. In the method of therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and/or fallopian tube obstruction (FTO), the improvement consisting of administration of an LHRH antagonist in the form of a short-term induction treatment for a period of about 4 to 12 weeks to a patient in need of such treatment, whereby subsequently the administration of the LHRH antagonist is ceased.
2. A method according to claim 1 wherein the LHRH antagonist is administered such that the estrogen serum concentration level is between about 35 pg/ml and about 80 pg/ml, preferably between about 45-75 pg/ml, more preferably about 50-75 pg/ml.
3. A method according to claim 1 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of a contraceptive, preferably an oral contraceptive.
4. A method according to claim 1 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of a non-steroidal anti- rheumatic agent.
5. A method according to claim 1 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of an analgetic.
6. A method according to claim 1 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of an androgen other than a 17-alpha-alkyl substituted testosterone.
7. A method according to claim 1 wherein the short-term induction treatment with the LHRH antagonist is followed by the combined or separate administration of one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or . any combinations thereof. ’
8. A method according to claim 1 wherein the LHRH antagonist is administered starting in the early to mid follicular phase, preferably on cycle day one to three.
9. A method according to claim 1 wherein the LHRH antagonist is selected from the group consisting of cetrorelix, teverelix, ganirelix, antide, abarelix and D-63153.
10.A method according to claim 1 wherein the LHRH antagonist is administered during the short-term induction treatment for about 4 to 12 weeks at a weekly dose of about 3 to 10 mg per week.
11:A method according to claim 1 wherein the LHRH antagonist is administered during the short-term induction treatment for about 4 to 12 weeks at a daily dose oo ofabout0.25mgto0.5mgday. ~~
12. A method according to claim 1 wherein the LHRH antagonist is administered during the short-term induction treatment for about 4 to 12 weeks at a monthly dose of about 12 to 40 mg per month.
13. A method according to claim 1 wherein the LHRH antagonist is given for the induction treatment during about 4 to 12 weeks and the treatment is repeated two or three times a year.
14.A pharmaceutical composition for treating extrauterine proliferation of endometrial tissue, chronic pelvic pain and/or fallopian tube obstruction (FTO) comprising an LHRH antagonist and optionally one or more agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non- steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha- alky! substituted testosterone or any combinations thereof, optionally together with pharmaceutically acceptable excipients, whereby the LH-RH antagonist is administered to a patient in need thereof in a short term induction treatment for a
‘. woe1n1194 2. PCT/EP00/09212 . period of about 4 to 12 weeks, then the administration of the LH-RH antagonist is ceased and optionally the one or more agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti- rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof, are administered together or separately to the patient.
15. Pharmaceutical composition according to claim 14 wherein the LHRH antagonist is administered such that the estrogen serum concentration level is between about 35 pg/ml and about 80 pg/ml, preferably between about 45-75 pg/ml, more preferably about 50-75 pg/ml.
16. Pharmaceutical composition according to claims 14 or 15 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of a contraceptive, preferably an oral contraceptive.
17. Pharmaceutical composition according to any one of the claims 14 to 16 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of a non-steroidal anti-rheumatic agent.
18. Pharmaceutical composition according to any one of the claims 14 to 17 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of an analgetic.
19. Pharmaceutical composition according to any one of the claims 14 to 18 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of an androgen other than a 17-alpha-alkyl substituted testosterone.
20. Pharmaceutical composition according to any one of the claims 14 to 19 wherein the short-term induction treatment with the LHRH antagonist is followed by the combined or separate administration of one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-
steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha- alky! substituted testosterone or any combinations thereof.
21. Pharmaceutical composition according to any one of the claims 14 to 20 wherein ‘the LHRH antagonist is administered starting in the early to mid follicular phase, . preferably on cycle day one to three.
22. A pharmaceutical composition according to any one of claims 14 to 21 wherein -the LHRH antagonist is selected from the group consisting of cetrorelix, teverelix, ganirelix, antide, abarelix and D-63153.
23. Pharmaceutical composition according to any one of claims 14 to 22 wherein the LHRH antagonist is administered during the short-term induction treatment for about 4 to 12 weeks at a weekly dose of about 3 to about 10 mg per week. oo
24. A pharmaceutical composition according to any one of claims 14 to 23 wherein the LHRH antagonist is administered during the short-term induction treatment se “for about 4 to 12 weeks at a daily dose of about 0.25 mg to about 0.5 mg/day.
25.Pharmaceutical composition according to any one of claims 14 to 24 wherein the LHRH antagonist is administered during the short-term induction treatment for about 4 to 12 weeks at a monthly dose of about 12 to 40 mg per month.
26. Pharmaceutical composition according to any one of claims 14 to 25 wherein the LHRH antagonist is given for the induction treatment during about 4 to 12 weeks and the treatment is repeated two or three times a year.
27. Pharmaceutical composition according to any one of claims 14 to 26, wherein the the one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof, are in the same or separate dosage forms.
‘Woon 24. PCT/EP00/09212 .
28.Use of an LH-RH antagonist for the preparation of a medicament for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and/or fallopian tube obstruction (FTO), whereby the LHRH antagonist is administered in the form of a short-term induction treatment for a period of about 4 to 12 weeks to a patient in need of such treatment and then the administration of the LHRH antagonist is ceased.
29. Use of an LH-RH antagonist according to claim 28 wherein the LHRH antagonist is administered such that the estrogen serum concentration level is between about 35 pg/m! and about 80 pg/ml, preferably between about 45-75 pg/ml, more preferably about 50-75 pg/ml.
30. Use of an LH-RH antagonist according to claim 28 or 29 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of a . contraceptive, preferably an oral contraceptive. ]
31. Use of an LH-RH antagonist according to any one of claims 28 to 30 wherein the: short-term induction treatment with the LHRH antagonist is followed by administration of a non-steroidal anti-rheumatic agent.
32. Use of an LH-RH antagonist according to any one of claims 28 to 31 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of an analgetic.
33. Use of an LH-RH antagonist according to any one of claims 28 to 32 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of an androgen other than a 17-alpha-alkyl substituted testosterone.
34. Use of an LH-RH antagonist according to any one of claims 28 to 33 wherein the short-term induction treatment with the LHRH antagonist is followed by the combined or separate administration of one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non- |, steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha- alkyl substituted testosterone or any combinations thereof.
35.Use of an LH-RH antagonist according to any one of claims 28 to 34 wherein the LHRH antagonist is administered starting in the early to mid follicular phase, preferably on cycle day one to three.
36. Use of an LH-RH antagonist according to any one of claims 28 to 35 wherein the LHRH antagonist is selected from the group consisting of cetrorelix, teverelix, ganirelix, antide, abarelix and D-63153. :
37. Use of an LH-RH antagonist according to any one of claims 28 to 36 wherein the LHRH antagonist is administered during the short-term induction treatment for about 4 to 12 weeks at a weekly dose of about 3 to about 10 mg per week. 3
38. Use of an LH-RH antagonist according to any one of claims 28 to 37 wherein the LHRH antagonist is administered during the short-term induction treatment for about 4 to 12 weeks at a daily dose of about 0.25 mg to about 0.5 mg/day.
39. Use of an LH-RH antagonist according to any one of claims 28 to 38 wherein the LHRH antagonist is administered during the short-term induction treatment for about 4 to 12 weeks at a monthly dose of about 12 to about 40 mg per month.
40. Use of an LH-RH antagonist according to any one of claims 28 to 39 wherein the LHRH antagonist is given for the induction treatment during about 4 to 12 weeks and the treatment is repeated two or three times a year.
41. Use of an LH-RH antagonist and one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non- steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha- alkyl substituted testosterone, or any combinations thereof, for the preparation of a medicament for the therapeutic management of extrauterine proliferation of
! WO00121194 2 PCT/EP00/09212 . endometrial tissue, chronic pelvic pain and/or fallopian tube obstruction (FTO), whereby the LHRH antagonist is administered in the form of a short-term induction treatment for a period of about 4 to 12 weeks to a patient in need of such treatment, then the administration of the LHRH antagonist is ceased and the one or more active agent selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic,c an androgen other than a 17-alpha-alkyl substituted testosterone, or any combinations thereof, are administered together or separately to the patient.
42. Use of an LH-RH antagonist and one or more active agents according to claim 41, wherein the LHRH antagonist is administered such that the estrogen serum concentration level is between about 35 pg/ml and about 80 pg/ml, preferably between about 45-75 pg/ml, more preferably about 50-75 pg/ml. i
43. Use of an LH-RH antagonist and one or more active agents according according to claims 41 or 42 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of a contraceptive, preferably: an oral contraceptive.
44. Use of an LH-RH antagonist and one or more active agents according according according to any one of claims 41 to 43 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of a non- steroidal anti-rheumatic agent.
45. Use of an LH-RH antagonist and one or more active agents according to any one of claims 41 to 44 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of an analgetic.
46. Use of an LH-RH antagonist and one or more active agents according to any one of claims 41 to 45 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of an androgen other than a 17-alpha- alkyl substituted testosterone.
47. Use of an LH-RH antagonist and one or more active agents according to any one of claims 41 to 46 wherein the short-term induction treatment with the LHRH antagonist is followed by the combined or separate administration of one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-heumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof.
48. Use of an LH-RH antagonist and one or more active agents according to any one of claims 41 to 47 wherein the LHRH antagonist is administered starting in the early to mid follicular phase, preferably on cycle day one to three.
49. Use of an LH-RH antagonist and one or more active agents according to any one of claims 41 to 48 wherein the LHRH antagonist is selected from the group consisting of cetrorelix, teverelix, ganirelix, antide, abarelix and D-63153.
50. Use of an LH-RH antagonist and one or more active agents according to any one of claims 41 to 49 wherein the LHRH antagonist is administered during the short- term induction treatment for about 4 to 12 weeks at a weekly dose of about 3 to 10 mg per week.
51. Use of an LH-RH antagonist and one or more active agents according to any one of claims 41 to 50 wherein the LHRH antagonist is administered during the short- term induction treatment for about 4 to 12 weeks at a daily dose of about 0.25 mg to 0.5 mg/day.
52. Use of an LH-RH antagonist and one or more active agents according to any one of claims 41 to 51 wherein the LHRH antagonist is administered during the short- term induction treatment for about 4 to 12 weeks at a monthly dose of about 12 to 40 mg per month.
YY wooer21194 PCT/EP00/09212 J -28- :
53. Use of an LH-RH antagonist and one or more active agents according to any one of claims 41 to 52 wherein the LHRH antagonist is given for the induction treatment during about 4 to 12 weeks and the treatment is repeated two or three times a year.
~
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15547899P | 1999-09-23 | 1999-09-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200201374B true ZA200201374B (en) | 2002-10-30 |
Family
ID=22555601
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200201374A ZA200201374B (en) | 1999-09-23 | 2002-02-19 | Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction. |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP1214086A2 (en) |
JP (2) | JP2003509467A (en) |
KR (1) | KR100772852B1 (en) |
CN (2) | CN101045155A (en) |
AU (1) | AU769482B2 (en) |
BG (1) | BG66128B1 (en) |
BR (1) | BR0014198A (en) |
CA (1) | CA2383510A1 (en) |
HK (1) | HK1049117A1 (en) |
HU (1) | HUP0202741A3 (en) |
IL (1) | IL148185A0 (en) |
MX (1) | MXPA02002436A (en) |
NO (1) | NO331198B1 (en) |
NZ (1) | NZ534836A (en) |
PL (1) | PL201898B1 (en) |
RU (1) | RU2255759C2 (en) |
SK (1) | SK3752002A3 (en) |
TR (1) | TR200200738T2 (en) |
TW (1) | TWI267373B (en) |
UA (1) | UA73956C2 (en) |
WO (1) | WO2001021194A2 (en) |
ZA (1) | ZA200201374B (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10157628A1 (en) * | 2001-11-26 | 2003-06-12 | Zentaris Ag | Solution for injection of an LHRH antagonist |
US7214662B2 (en) | 2001-11-27 | 2007-05-08 | Zentaris Gmbh | Injectable solution of an LHRH antagonist |
EP2252627B1 (en) | 2008-01-24 | 2017-04-19 | Esperance Pharmaceuticals | Lytic domain fusion constructs and methods of making and using same |
WO2010085145A1 (en) * | 2009-01-22 | 2010-07-29 | Maatschap Interne Geneeskunde Rijnstate | Method for the prophylaxis or treatment of flushing |
AU2013337926B2 (en) | 2012-10-30 | 2017-12-21 | Esperance Pharmaceuticals, Inc. | Antibody/drug conjugates and methods of use |
EP3384930A1 (en) | 2013-03-15 | 2018-10-10 | AbbVie Inc. | Compositions for use in treating heavy menstrual bleeding |
AU2018419533A1 (en) | 2018-04-19 | 2020-11-12 | Abbvie Inc. | Methods of treating heavy menstrual bleeding |
EP3560555A1 (en) * | 2018-04-26 | 2019-10-30 | LifeArc | A composition for treating one or more estrogen related diseases |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5064939A (en) * | 1990-02-06 | 1991-11-12 | The Salk Institute For Biological Studies | Cyclic gnrh antagonists |
SE9301606D0 (en) * | 1993-05-07 | 1993-05-07 | Per-Christer Oden | COMPOSITION FOR THE TREATMENT OF IMPAIRED HAIR GROWTH |
US5658884A (en) * | 1994-07-22 | 1997-08-19 | The Medical College Of Hampton Roads | Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens |
ATE190494T1 (en) * | 1994-07-22 | 2000-04-15 | Hampton Roads Medical College | USE OF GNRH ANTAGONISTS FOR PRODUCING A MEDICATION FOR TREATING GONAD STEROID DEPENDENT DISEASES |
DE19513662A1 (en) * | 1995-04-08 | 1996-10-10 | Schering Ag | Combined pharmaceutical preparation for hormonal contraception |
DE19604231A1 (en) * | 1996-01-29 | 1997-07-31 | Schering Ag | Combined pharmaceutical preparation and its use for the treatment of gynecological disorders |
CN1228708A (en) * | 1996-09-04 | 1999-09-15 | 有限会社多特 | Peptide-containing drug compositions for oral administration |
CA2292605A1 (en) * | 1997-06-05 | 1998-12-10 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
DE19911771B4 (en) * | 1999-03-17 | 2006-03-30 | Zentaris Gmbh | LHRH antagonist, process for its preparation and its use |
-
2000
- 2000-09-20 WO PCT/EP2000/009212 patent/WO2001021194A2/en active IP Right Grant
- 2000-09-20 IL IL14818500A patent/IL148185A0/en not_active IP Right Cessation
- 2000-09-20 CA CA002383510A patent/CA2383510A1/en not_active Abandoned
- 2000-09-20 CN CNA2007100789192A patent/CN101045155A/en active Pending
- 2000-09-20 TR TR2002/00738T patent/TR200200738T2/en unknown
- 2000-09-20 PL PL353244A patent/PL201898B1/en not_active IP Right Cessation
- 2000-09-20 RU RU2002111000/14A patent/RU2255759C2/en not_active IP Right Cessation
- 2000-09-20 CN CN00813196A patent/CN1376070A/en active Pending
- 2000-09-20 UA UA2002043346A patent/UA73956C2/en unknown
- 2000-09-20 AU AU77792/00A patent/AU769482B2/en not_active Ceased
- 2000-09-20 SK SK375-2002A patent/SK3752002A3/en not_active Application Discontinuation
- 2000-09-20 HU HU0202741A patent/HUP0202741A3/en unknown
- 2000-09-20 JP JP2001524618A patent/JP2003509467A/en not_active Withdrawn
- 2000-09-20 NZ NZ534836A patent/NZ534836A/en not_active IP Right Cessation
- 2000-09-20 EP EP00967722A patent/EP1214086A2/en not_active Withdrawn
- 2000-09-20 MX MXPA02002436A patent/MXPA02002436A/en active IP Right Grant
- 2000-09-20 KR KR1020027003740A patent/KR100772852B1/en not_active IP Right Cessation
- 2000-09-20 BR BR0014198-4A patent/BR0014198A/en not_active Application Discontinuation
- 2000-09-22 TW TW089119671A patent/TWI267373B/en not_active IP Right Cessation
-
2002
- 2002-02-19 ZA ZA200201374A patent/ZA200201374B/en unknown
- 2002-03-21 NO NO20021430A patent/NO331198B1/en not_active IP Right Cessation
- 2002-04-05 BG BG106584A patent/BG66128B1/en unknown
-
2003
- 2003-02-18 HK HK03101215.4A patent/HK1049117A1/en unknown
-
2011
- 2011-10-17 JP JP2011227603A patent/JP2012051920A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2001021194A2 (en) | 2001-03-29 |
HK1049117A1 (en) | 2003-05-02 |
NZ534836A (en) | 2007-07-27 |
HUP0202741A3 (en) | 2003-12-29 |
JP2012051920A (en) | 2012-03-15 |
AU769482B2 (en) | 2004-01-29 |
RU2255759C2 (en) | 2005-07-10 |
NO20021430L (en) | 2002-05-07 |
BG106584A (en) | 2003-02-28 |
EP1214086A2 (en) | 2002-06-19 |
HUP0202741A2 (en) | 2003-01-28 |
UA73956C2 (en) | 2005-10-17 |
SK3752002A3 (en) | 2003-06-03 |
BG66128B1 (en) | 2011-06-30 |
CN1376070A (en) | 2002-10-23 |
BR0014198A (en) | 2002-05-21 |
AU7779200A (en) | 2001-04-24 |
KR20020035879A (en) | 2002-05-15 |
WO2001021194A3 (en) | 2002-03-14 |
TR200200738T2 (en) | 2002-08-21 |
IL148185A0 (en) | 2002-09-12 |
TWI267373B (en) | 2006-12-01 |
NO20021430D0 (en) | 2002-03-21 |
MXPA02002436A (en) | 2003-02-12 |
JP2003509467A (en) | 2003-03-11 |
PL353244A1 (en) | 2003-11-03 |
PL201898B1 (en) | 2009-05-29 |
CA2383510A1 (en) | 2001-03-29 |
NO331198B1 (en) | 2011-10-31 |
KR100772852B1 (en) | 2007-11-02 |
CN101045155A (en) | 2007-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2281551T3 (en) | METHOD OF PREVENTION OR TREATMENT OF BENIGN GYNECOLOGICAL DISEASES. | |
US20070111975A1 (en) | Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens | |
Erkkola et al. | Role of progestins in contraception | |
JP2012051920A (en) | Pharmaceutical composition for treatment of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction, lhrh antagonist for manufacturing drugs to treat the diseases or lhrh antagonist and active agent | |
KR20110021709A (en) | Use of ulipristal for treating uterine fibroids | |
JP5543920B2 (en) | Treatment of estrogen-dependent symptoms in premenopausal women | |
Cheng et al. | Medical treatment for uterine myomas | |
US7666836B2 (en) | Method for the therapeutic management of endometriosis | |
Bedaiwy et al. | Aromatase inhibitors prevent the estrogen rise associated with the flare effect of gonadotropins in patients treated with GnRH agonists | |
JP2012077020A (en) | Combination medicine of gestagen and gnrh antagonist | |
JP3925688B2 (en) | Pharmaceutical formulation for treating side effects during and / or after GnRHa treatment | |
Adegoke et al. | GnRH Antagonists in the Treatment of Uterine Fibroids | |
Wong et al. | Exogenous Hormone-Induced Endometrial Changes | |
Patel | Response of the Uterus to Medication: Hysteroscopic Implications | |
Patel | 6 Hysteroscopic Implications | |
US20020002153A1 (en) | Pharmaceutical preparations for treating side effects during and/or after gnrha therapy | |
Telimaa et al. | High-Dose Medroxyprogesterone Acetate and Danazol in the Treatment of Endometriosis |